IISc Spin-Out Venomics AI Raises $2.7 Mn To Turn Venom Into Drugs

Venomics AI, a biotechnology company spun out of the Indian Institute of Science, has raised $2.7 million in a pre-seed round co-led by Speciale Invest and South Park Commons. Operators Studio also participated.

It is the Bengaluru-based company’s first institutional funding round. The money will go into expansion, growing its molecular dataset and strengthening its AI and laboratory screening capabilities.

What Venomics AI Does

The Venomics AI platform combines venom biology, molecular sequencing, artificial intelligence and experimental screening to find and develop venom-derived therapeutic leads.

Read More: Desiya Suraksha Party Unveils National Mission for Safety and Citizens’ Welfare

FundingDelhi Oncology Startup ZoeNCure Raises Rs 20 Cr For Cancer TherapyFundingQNu Labs Raises Rs 200 Crore For Quantum Safe Security

Venom is one of the densest sources of biologically active molecules in nature. A single species can carry hundreds of peptides that act on the nervous system, on blood clotting or on cell membranes. Most of them have never been characterised.

Read More: Crazy Cock Named Best Indian Single Malt Whisky At IWSC 2026

Venomics AI is building a Venom Atlas, a dataset that connects venom-derived molecular data with laboratory validation and drug discovery. The atlas is the core asset; the models and the assays are how it gets used.

The Loop That Matters

The Venomics AI platform sequences venom molecules to build the atlas, uses AI to prioritise which candidates are worth testing, then runs functional screening in the laboratory.

Those experimental results feed back into the next round of predictions and molecular design. That feedback loop is what separates a discovery platform from a database.

For Venomics AI, it is also the hardest part to build. A model that predicts on unvalidated data is a guess; a model that is corrected by wet-lab results every cycle improves.

Why India Is a Rational Place to Build This

India holds extraordinary venom biodiversity, spread across snakes, scorpions, spiders and marine species in several distinct ecological zones.

The country also has the scientific and computational talent to study it. What it has lacked is a company that treats venom as a systematic dataset rather than a collection of individual research projects.

Venomics AI was co-founded in May 2026 by Sunagar and Vinay Prabhu. Has already established the initial architecture of its platform.

The Traction Available at Pre-Seed

Venomics AI is also working in a field where India has an unusual advantage. Much of the global research on snake venoms has been done on species found in Africa, Australia and the Americas. Indian species are comparatively under-studied.

For a company this young, two signals are worth noting. It has joined the NVIDIA Inception programme. It was selected among the top five finalists for the 2026 Indo-Boston Biotech Bridge Award.

Neither is revenue. Both indicate that the scientific premise has passed review by people who understand the field.

Venomics AI plans to build a multidisciplinary team across venom biology, computational science and drug discovery. To support validation and optimisation of promising molecules.

What to Watch

Drug discovery timelines are long. A pre-seed company in this space is funded on the strength of its platform rather than its pipeline. That makes the next two years a test of data quality, not of sales.

Three things will decide whether this becomes a drug discovery company or a well-funded research group. The first is a published hit rate, meaning how often an AI-prioritised candidate survives laboratory screening.

The second is the depth of the atlas. A dataset of a few hundred peptides is a start; a dataset that covers thousands of species is a moat.

The third is partnership. Venom-derived drugs take a decade and hundreds of millions to reach patients. The realistic path is licensing leads to a larger pharma partner rather than developing them alone.